Results 151 to 160 of about 2,223,665 (257)

Long noncoding RNA DDX11-AS1 represses sorafenib-induced ferroptosis in hepatocellular carcinoma cells via Nrf2-Keap1 pathway

Discover Oncology
Sorafenib, a first-line therapeutic option for advanced hepatocellular carcinoma (HCC), faces a formidable challenge in the form of emerging resistance.
Liang Wang, Liming Wang
doaj   +1 more source

Selective use of sorafenib in the treatment of thyroid cancer

, 2016
Fabián Pitoia, Fernando Jerkovich Division of Endocrinology, Hospital de Clinicas – University of Buenos Aires, Buenos Aires, Argentina Abstract: Sorafenib is a multiple kinase inhibitor (MKI) approved for the treatment of primary advanced
Pitoia F, Jerkovich F
core  

VEGF inhibitor‐induced vascular dysfunction involves redox‐sensitive PARP activation and SIRT1 disruption

Experimental Physiology, EarlyView.
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Karla B. Neves, Rheure Alves‐Lopes, Augusto C. Montezano, Rhian M. Touyz   +3 more
wiley   +1 more source

Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer

International Journal of Cancer, Volume 159, Issue 8, Page 1974-1989, 15 October 2026.
Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Celina Ablinger, Petra Huber‐Cantonati, Daniela D. Weber, Sarah Pichler, Georg Schischkow, Marta Garcia‐Miralles, Christian Pirich, Gundula Rendl, Teresa Kiener, Thomas Felder, Martin Geroldinger, Robert Terkola, Barbara Kofler, Johanna Pachmayr   +13 more
wiley   +1 more source

Exploring the Anticancer Potential of Schiff Base Complexes: A Mini‐Review

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
Schiff base metal complexes as promising anticancer agents: highlighting DNA interactions, cytotoxicity, molecular targets, and mechanisms of cancer cell death. Schiff bases are well known for their ability to form stable coordination compounds with several transition metals, making them valuable for medicinal chemistry purposes.
Atif Ahmad, Anam, Marcos V. Palmeira‐Mello, Sabir Khan, José Clayston Melo Pereira   +4 more
wiley   +1 more source

A Chemical Framework for Engineering Extracellular Vesicles’ Biointerface to Advance Precision Therapeutics

Advanced Materials, Volume 38, Issue 52, 16 September 2026.
Extracellular vesicles (EVs) are cell‐derived nanoparticles that mediate intercellular communication through their dynamic biointerfaces. Owing to their intrinsic biological functions, EVs have emerged as promising platforms for biomedical applications.
Leila Pourtalebi Jahromi, Felix Geng, Jan‐Noël Frenzke, Gregor Fuhrmann   +3 more
wiley   +1 more source

Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines

, 2017
Introduction: Although sorafenib enhances overall survival, sorafenib resistance has been reported to be a significant limiting factor for improved prognosis in patients with hepatocellular carcinoma (HCC).
최광현
core  

Single‐Cell Reveal GALNT7‐Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non‐Small Cell Lung Cancer

Advanced Science, Volume 13, Issue 50, 7 September 2026.
Integrated clinical and mechanistic analyses identify GALNT7 as a ferroptosis‐suppressive regulator associated with immunotherapy resistance in non‐small cell lung cancer. GALNT7 depletion promotes lipid peroxidation, mitochondrial dysfunction, and ferroptosis, enhances CD8+ T‐cell activation and IFN‐γ production, and sensitizes tumors to PD‐1 blockade,
Jiadi Gan, Qian Zheng, Deng Liu, Ruichao Nie, Menglin Yao, Xiaolong Tang, Renjie Xu, Jinghong Xian, Wenjun Meng, Wenxin Luo, Dan Liu, Guiyi Ji   +11 more
wiley   +1 more source

Image_3_IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.pdf

IntroductionSorafenib is currently the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, sorafenib resistance remains a huge challenge in the clinic.
Chidan Wan (144282), Junzhang Chen (12427704), Hui Li (32376), Xiong Cai (140594), Shiran Sun (14095587)   +4 more
core   +1 more source

Cholesterol Laundry of Cell Membrane and Fatty Liver by Detergent Liposomes to Improve Anti‐Cancer Drug Responsiveness of Patient Liver Tissues

Advanced Science, Volume 13, Issue 51, 14 September 2026.
Cholesterol‐enriched plasma membranes in hepatocellular carcinoma impede drug penetration. Cholesterol (+)‐liposomes act as membrane‐specific detergents, extracting cholesterol and reducing barrier function without cytotoxicity. Following endocytosis, cholesterol transfers from endosomes to liposomes and is metabolized in the ER.
Chansik Kim, Joo Kyung Noh, Sewoom Baek, Seung Eun Yu, Jueun Kim, Seongyo Lee, Youngji Oh, Dai Hoon Han, Seyong Chung, Hak‐Joon Sung   +9 more
wiley   +1 more source